| Fund Raise | ₹10.01 CrAggregate Issue |
|---|---|
| Market Cap | ₹215.72 CrMicro Cap |
| Revenue TTM | ₹190.71 CrOperating Income |
| Day RSI | 66.7Neutral/Strong |
| Deal value | ₹10.01 Cr |
| Share of market cap | 4.6% |
Key highlights
- Approved issuance of 1,12,500 equity shares at a fixed price of ₹178 per share
- Issuance of 4,50,000 convertible warrants at ₹178 each to the promoter group
- Total aggregate fund raise valued at ₹10.01 Crore across both instruments
- Managing Director Sunil L. Mundra's stake to increase from 5.79% to 10.61% post-conversion
- Warrant holders to pay 25% upfront with an 18-month window to exercise the balance
What Is the Fund Raise?
The Board of Directors approved a preferential issue comprising 1,12,500 equity shares and 4,50,000 convertible warrants at a fixed price of ₹178 per unit. This issuance totals approximately ₹10.01 Crore. The pricing was revised based on a valuation report dated August 31, 2026, following queries from the stock exchanges.
While the equity shares require full payment upon allotment, the warrants involve a 25% upfront payment of ₹44.50 per warrant, with the remaining 75% payable within an 18-month exercise window. This capital infusion is directed toward the promoter group, specifically Mr. Sunil L.
Mundra, strengthening internal stakeholder commitment to the company's long-term trajectory.
Strategic Rationale
The preferential issuance primarily targets the promoter group, signaling a significant vote of confidence from the company leadership. Upon the full conversion of the 4,50,000 warrants into equity shares, the personal shareholding of Managing Director Sunil L. Mundra is projected to increase from 5.79% to 10.61%.
This move not only provides the company with immediate liquidity through equity and warrant subscription fees but also aligns management interests more closely with public shareholders. The fundraise comes at a time when the company is navigating a transition phase, as evidenced by its recent financial performance and the need for stable growth capital.
Business Overview
- Natural Capsules is a key Indian manufacturer of hard gelatin and cellulose capsule shells for the pharmaceutical and dietary supplement sectors.
- The company operates two primary manufacturing units located in Bangalore and Pondicherry to serve domestic and export markets.
- Product offerings include specialized variants such as liquid-fill capsules and preservative-free options tailored for sensitive drug formulations.
- The firm holds ISO 9001, 14001, and OHSAS 18001 certifications, maintaining global quality standards for specialized capsule manufacturing.
Financial Context
Natural Capsules currently holds a market capitalization of approximately ₹215.72 Crore. For the trailing twelve months, the company reported an operating revenue of ₹190.71 Crore, though it faced a net loss of ₹21.53 Crore. This capital raise follows a period where the stock has shown significant momentum, with a one-month price increase of 44.61% and a one-week surge of 24.16%.
The issue price of ₹178 per share is set against a current market price of ₹207.2. Despite a low Piotroski Score of 2, the promoter's decision to inject capital suggests a strategic focus on stabilizing the balance sheet and supporting ongoing operations.
| Share price | ₹207.2 |
|---|---|
| Market capitalisation | ₹215.72 Cr |
| Revenue (annual) | ₹187.20 Cr |
| Net profit (annual) | -₹24.66 Cr |
| Revenue (latest quarter) | ₹48.71 Cr-16.67% vs previous quarter |
| Net profit (latest quarter) | -₹3.98 Cr-15.41% vs previous quarter |
| P/E (TTM) | -10.02×Sector 46.59× |
| Promoter holding | 50.92%-0.12% QoQ |
| FII holding | 0%Current quarter |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
Exchange filing by Natural Capsules Limited announcing the outcome of the Board Meeting regarding a preferential issue of shares and warrants. Market figures from a third-party data provider.
